Assessment of late anthracycline-induced cardiotoxicity by 123I-mIBG cardiac scintigraphy in patients treated during childhood and adolescence

• Published in: Journal of nuclear cardiology Vol. 24; no. 1; pp. 256 - 264
• Main Authors: dos Santos, Marcelo José, da Rocha, Euclides Timóteo, Verberne, Hein J., da Silva, Eduardo Tinois, Aragon, Davi Casale, Junior, José Soares
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 01-02-2017; Springer US
• Subjects: 123I-mIBG; anthracycline; Cardiac sympathetic activity; Cardiology; Imaging; left ventricular function; Medicine; Medicine & Public Health; Nuclear Medicine; Original Article; Radiology; ATC; left ventricular function; anthracycline; Cardiac sympathetic activity; 123I-mIBG; H/M; NE; LVEF; WR; PFR; ROI; HF; I; IBG
• ISSN: 1071-3581; 1532-6551
• DOI: 10.1007/s12350-015-0309-y

The goal of this study was to evaluate late cardiotoxic effects of anthracyclines (ATC) by evaluating cardiac sympathetic activity in a cohort of asymptomatic patients previously treated with ATC for childhood cancers.
We studied 89 asymptomatic patients previously treated with ATC with a normal echocardiogram (49 men and 40 women) and a control group of 40 healthy individuals (26 men and 14 women). Both groups underwent planar myocardial 123I-meta-iodobenzylguanidine scintigraphy (123I-mIBG). From these images, the early and late heart-to-mediastinum (H/M) ratio and washout rate (WR) were assessed.
The mean survival at the time of the 123I-mIBG scintigraphy was 5.3 ± 3.4 years. Patients treated with ATC had a lower but clinical normal left ventricular ejection fraction (LVEF) compared to controls (60.44 ± 6.5 vs 64.1 ± 6.0%, P < 0.01). Both the late H/M ratio and WR were not able to discriminate ATC treated patients from controls. The cumulative ATC dose was the only independent predictor of the LVEF, explaining approximately 12% of the variation in LVEF (P = 0.01).
Although the pathophysiology behind ATC cardiotoxicity is most likely multifactorial, myocardial sympathetic activity is not associated with a reduction in LVEF 5-years after completion of chemotherapy.